Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%
March 17, 2022 at 14:19 PM EDT
Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.
 |
||||||||||||
|
||||||||||||
| About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map | ||||||||||||
Photos copyright by Jay Graham Photographer
